Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Positive Non-small Cell Lung Cancer”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Not applicableUnknownNCT05110950
What this trial is testing

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Who this might be right for
Mediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more
Università Politecnica delle Marche 306
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Testing effectiveness (Phase 2)UnknownNCT05004974
What this trial is testing

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 20
Testing effectiveness (Phase 2)WithdrawnNCT04470674
What this trial is testing

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Who this might be right for
Lung CancerNon-small Cell Lung CancerPD-L1 Gene Mutation+1 more
Shirish M Gadgeel
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05879822
What this trial is testing

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Who this might be right for
Advanced Solid Tumor
Incyte Corporation 73
Testing effectiveness (Phase 2)WithdrawnNCT05879484
What this trial is testing

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Who this might be right for
Sinonasal CancerSquamous Non-small Cell Lung CancerLung Cancer+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06982924
What this trial is testing

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
Shanghai Chest Hospital 136
Early research (Phase 1)Study completedNCT02007070
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 38
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Not applicableUnknownNCT04322591
What this trial is testing

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04622007
What this trial is testing

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Who this might be right for
Non-small Cell Lung Cancer
Effector Therapeutics 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT03620669
What this trial is testing

1st Line Durvalumab in PS 2 NSCLC Patients

Who this might be right for
NSCLC Stage IVNSCLC Stage IIIB
Swiss Cancer Institute 48
Testing effectiveness (Phase 2)Looking for participantsNCT07264647
What this trial is testing

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Stage III NSCLC
Fondazione Ricerca Traslazionale 30
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04198766
What this trial is testing

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Who this might be right for
Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+4 more
Inhibrx Biosciences, Inc 296
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Large-scale testing (Phase 3)Study completedNCT02220894
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 1,274
Load More Results